Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is ...
Adhera Therapeutics reported revenue of $0 for fiscal year 2022, and net income of -$2.73 million. In Q3 2023 (the quarter ended September 30, 2023) revenue was $0.
Figures from company filings; latest fiscal year ended December 31, 2022.
From state WARN notices, SEC filings and news reports. Reported: news reports only. Confirmed: an official filing exists.
Adhera Therapeutics had 0 layoffs in the last 12 months, and 3 in all (the earliest dated November 21, 2007).
Layoffs, 12 months
0
Workers not stated
Layoffs in all
3
Earliest dated Nov 21, 2007
Workers in all
145
Where the sources state it
Newest layoff
Aug 4, 2008
Announced date
| Date | Place | Workers | Status | Sources |
|---|---|---|---|---|
| Aug 4, 2008 | United States | 23 | Confirmed | SEC 8-K |
| Feb 13, 2008 | United States | 50 | Confirmed | SEC 8-K |
| Nov 21, 2007 | United States | 72 | Confirmed | SEC 8-K |
No profile data available.